PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors

Phase 1 Completed University of Wisconsin, Madison National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining PS-341 and doxorubicin in treating patients who have advanced solid tumors.

Timeline

Start: 2001-06
Primary completion: 2003-10
Completion: —

Publications

Results LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2008 Dec;63(1):109-15. doi: 10.1007/s00280-008-0719-5. Epub 2008 Mar 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1 mg/m2	Intravenous
Subject	Bortezomib	Small molecule	1.3 mg/m2	Intravenous
Subject	Bortezomib	Small molecule	1.5 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	15 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	20 mg/m2	Intravenous

PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications